{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:45:43Z","timestamp":1787507143413,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several anti-malarial drugs have been evaluated in randomized clinical trials to treat acute uncomplicated\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria. The outcome of anti-malarial drug efficacy studies is classified into one of four possible outcomes defined by the World Health Organization: adequate clinical and parasitological response, late parasitological failure, late clinical failure, early treatment failure. These four ordered categories are ordinal data, which are reduced to either a binary outcome (i.e., treatment success and treatment failure) to calculate the proportions of treatment failure or to time-to-event outcome for Kaplan\u2013Meier survival analysis. The arbitrary transition from 4-level ordered categories to 2-level type categories results in a loss of statistical power. In the opinion of the authors, this outcome can be considered as ordinal at a fixed endpoint or at longitudinal endpoints. Alternative statistical methods can be applied to 4-level ordinal categories of therapeutic response to optimize data exploitation. Furthermore, network meta-analysis is useful not only for direct comparison of drugs which were evaluated together in a randomized design, but also for indirect comparison of different artemisinin-based combinations across different clinical studies using a common drug comparator, with the aim to determine the ranking order of drug efficacy. Previous works conducted in Cameroonian children served as data source to illustrate the feasibility of these novel statistical approaches. Data analysis based on ordinal end-point may be helpful to gain further insight into anti-malarial drug efficacy.\n                  <\/jats:p>","DOI":"10.1186\/s12936-021-03768-1","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T04:03:04Z","timestamp":1621569784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Methodological approaches for analysing data from therapeutic efficacy studies"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-5275","authenticated-orcid":false,"given":"Solange","family":"Whegang Youdom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo K.","family":"Basco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"3768_CR1","unstructured":"WHO. Assessment and monitoring of anti-malarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003."},{"key":"3768_CR2","unstructured":"WHO. Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"3768_CR3","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva: World Health Organization; 2015."},{"key":"3768_CR4","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva: World Health Organization; 2020."},{"key":"3768_CR5","unstructured":"WHO. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO\/MAL\/96.1077, Geneva: World Health Organization; 1996."},{"key":"3768_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12936-017-2074-7","volume":"16","author":"P Dahal","year":"2017","unstructured":"Dahal P, Simpson JA, Dorsey G, Gu\u00e9rin PJ, Price RN, Stepniewska K. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malar J. 2017;16:430.","journal-title":"Malar J"},{"key":"3768_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1475-2875-5-127","volume":"5","author":"K Stepniewska","year":"2006","unstructured":"Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127.","journal-title":"Malar J"},{"key":"3768_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12936-019-2837-4","volume":"18","author":"WorldWide Antimalarial Resistance Network Methodology Study Group","year":"2019","unstructured":"WorldWide Antimalarial Resistance Network Methodology Study Group. Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis. Malar J. 2019;18:225.","journal-title":"Malar J"},{"key":"3768_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2288-10-58","volume":"10","author":"SY Whegang","year":"2010","unstructured":"Whegang SY, Basco LK, Gw\u00e9t H, Thalabard JC. Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3-arm anti-malarial drug trial in Cameroon. BMC Med Res Methodol. 2010;10:58.","journal-title":"BMC Med Res Methodol"},{"key":"3768_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1475-2875-11-147","volume":"11","author":"S Whegang Youdom","year":"2012","unstructured":"Whegang Youdom S, Samson A, Basco LK, Thalabard JC. Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations. Malar J. 2012;11:147.","journal-title":"Malar J"},{"key":"3768_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12936-017-1963-0","volume":"16","author":"S Whegang Youdom","year":"2017","unstructured":"Whegang Youdom S, Tahar R, Basco LK. Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. Malar J. 2017;16:311.","journal-title":"Malar J"},{"key":"3768_CR12","doi-asserted-by":"publisher","first-page":"100401","DOI":"10.1016\/j.conctc.2019.100401","volume":"15","author":"RL Peterson","year":"2019","unstructured":"Peterson RL, Vock DM, Babiker A, Powers JH 3rd, Hunsberger S, Angus B, et al. Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization. Contemp Clin Trials Commun. 2019;15:100401.","journal-title":"Contemp Clin Trials Commun"},{"key":"3768_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.2517-6161.1980.tb01109.x","volume":"42","author":"P McCullagh","year":"1980","unstructured":"McCullagh P. Regression models for ordinal data. J R Statist Soc B. 1980;42:109\u201342.","journal-title":"J R Statist Soc B"},{"key":"3768_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/0470114754","volume-title":"An introduction to categorical data analysis","author":"A Agresti","year":"2007","unstructured":"Agresti A. An introduction to categorical data analysis. 2nd ed. New Jersey: John Wiley & Sons, Inc.; 2007.","edition":"2"},{"key":"3768_CR15","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/sim.919","volume":"20","author":"A Whitehead","year":"2001","unstructured":"Whitehead A, Omar RZ, Higgins JP, Savaluny E, Turner RM, Thompson SG. Meta-analysis of ordinal outcomes using individual patient data. Stat Med. 2001;20:2243\u201360.","journal-title":"Stat Med"},{"key":"3768_CR16","doi-asserted-by":"crossref","unstructured":"Harrell FE Jr. Ordinal logistic regression. In: Regression modeling strategies. Springer Series in Statistics. Springer, New York, NY; 2001. p. 331\u201343.","DOI":"10.1007\/978-1-4757-3462-1_13"},{"key":"3768_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2875-13-9","volume":"13","author":"D Djalle","year":"2014","unstructured":"Djalle D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine\u2013pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.","journal-title":"Malar J"},{"key":"3768_CR18","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105\u201324.","journal-title":"Stat Med"},{"key":"3768_CR19","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/"},{"key":"3768_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cmpb.2009.05.004","volume":"97","author":"JL Foulley","year":"2010","unstructured":"Foulley JL, Jaffr\u00e9zic F. Modelling and estimating heterogeneous variances in threshold models for ordinal discrete data via Winbugs\/Openbugs. Comput Methods Programs Biomed. 2010;97:19\u201327.","journal-title":"Comput Methods Programs Biomed"},{"key":"3768_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417\u201328.","journal-title":"Value Health"},{"key":"3768_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health"},{"key":"3768_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/1475-2875-12-385","volume":"12","author":"O Egunsola","year":"2013","unstructured":"Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J. 2013;12:385.","journal-title":"Malar J"},{"key":"3768_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/jrsm.1256","volume":"8","author":"A B\u00e9liveau","year":"2017","unstructured":"B\u00e9liveau A, Goring S, Platt RW, Gustafson P. Network meta-analysis of disconnected networks: how dangerous are random baseline treatment effects? Res Synth Methods. 2017;8:465\u201374.","journal-title":"Res Synth Methods"},{"key":"3768_CR25","first-page":"49","volume":"64","author":"A Konat\u00e9","year":"2018","unstructured":"Konat\u00e9 A, Barro-Kiki PCM, Angora KE, B\u00e9dia-Tanoh AV, Djohan V, Kassi KF, et al. Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across C\u00f4te d\u2019Ivoire. Ann Parasitol. 2018;64:49\u201357.","journal-title":"Ann Parasitol"},{"key":"3768_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.11604\/pamj.2020.35.68.20849","volume":"35","author":"I Zongo","year":"2020","unstructured":"Zongo I, Compaor\u00e9 YD, Niki\u00e9ma F, Zongo M, Barry N, Som\u00e9 FA, et al. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan Afr Med J. 2020;35:68.","journal-title":"Pan Afr Med J"},{"key":"3768_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(20)30064-5","volume":"20","author":"M Saito","year":"2020","unstructured":"Saito M, Mansoor R, Kennon K, Anvikar AR, Ashley EA, Chandramohan D, et al. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2020;20:943\u201352.","journal-title":"Lancet Infect Dis"},{"key":"3768_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12936-018-2200-1","volume":"17","author":"F Grandesso","year":"2018","unstructured":"Grandesso F, Guindo O, Woi Messe L, Makarimi R, Traore A, Dama S, et al. Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi. Niger Malar J. 2018;17:52.","journal-title":"Niger Malar J"},{"key":"3768_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","volume":"4","author":"C Cameron","year":"2015","unstructured":"Cameron C, Fireman B, Hutton B, Clifford T, Coyle D, Wells G, et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015;4:147.","journal-title":"Syst Rev"},{"key":"3768_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98\u2013110.","journal-title":"Res Synth Methods"},{"key":"3768_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jrsm.1103","volume":"5","author":"CH Schmid","year":"2014","unstructured":"Schmid CH, Trikalinos TA, Olkin I. Bayesian network meta-analysis for unordered categorical outcomes with incomplete data. Res Synth Methods. 2014;5:162\u201385.","journal-title":"Res Synth Methods"},{"key":"3768_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, Brenner D, Arora P. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med Res Methodol. 2019;19:196.","journal-title":"BMC Med Res Methodol"},{"key":"3768_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-018-0259-3","volume":"19","author":"S Whegang Youdom","year":"2019","unstructured":"Whegang Youdom S, Chiabi A, Basco LK. Monitoring the efficacy and safety of artemisinin-based combination therapies: a review and network meta-analysis of antimalarial therapeutic efficacy trials in Cameroon. Drugs R D. 2019;19:1\u201314.","journal-title":"Drugs R D"},{"key":"3768_CR34","doi-asserted-by":"publisher","first-page":"e0225882","DOI":"10.1371\/journal.pone.0225882","volume":"14","author":"C Naing","year":"2019","unstructured":"Naing C, Whittaker MA, Htet NH, Aye SN, Mak JW. Efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in Asian region: A network meta-analysis. PLoS ONE. 2019;14:e0225882.","journal-title":"PLoS ONE"},{"key":"3768_CR35","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9:e99682.","journal-title":"PLoS ONE"},{"key":"3768_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"3768_CR37","doi-asserted-by":"crossref","unstructured":"Efthimiou O, Debray TP, van Valkenhoef G, Trelle S, Panayidou K, Moons KG, Reitsma JB, Shang A, Salanti G; GetReal Methods Review Group. GetReal in network meta-analysis: a review of the methodology. Res Synth Methods. 2016;7:236-63.","DOI":"10.1002\/jrsm.1195"},{"key":"3768_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/hep.31070","volume":"72","author":"G D\u2019Amico","year":"2020","unstructured":"D\u2019Amico G, Abraldes JG, Rebora P, Valsecchi MG, Garcia-Tsao G. Ordinal outcomes are superior to binary outcomes for designing and evaluating clinical trials in compensated cirrhosis. Hepatology. 2020;72:1029\u201342.","journal-title":"Hepatology"},{"key":"3768_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12936-019-2885-9","volume":"18","author":"CC Stanley","year":"2019","unstructured":"Stanley CC, Kazembe LN, Mukaka M, Otwombe KN, Buchwald AG, Hudgens MG, et al. Systematic review of analytical methods applied to longitudinal studies of malaria. Malar J. 2019;18:254.","journal-title":"Malar J"},{"key":"3768_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2202\/1557-4679.1230","volume":"6","author":"M Manuguerra","year":"2010","unstructured":"Manuguerra M, Heller GZ. Ordinal regression models for continuous scales. Int J Biostat. 2010;6:14.","journal-title":"Int J Biostat"},{"key":"3768_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11908-010-0099-y","volume":"12","author":"JT Lin","year":"2010","unstructured":"Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2010;12:165\u201373.","journal-title":"Curr Infect Dis Rep"},{"key":"3768_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03768-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03768-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:12:38Z","timestamp":1725081158000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03768-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03768-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}